Recommendation ID

Metformin preparations for children and young people with type 2 diabetes:- What is the long-term comparative clinical and cost effectiveness of different metformin preparations for treating type 2 diabetes in children and young people?

Any explanatory notes
(if applicable)

Why this is important:- There is high-quality evidence for the clinical and cost effectiveness of metformin as a treatment for type 2 diabetes from diagnosis in children and young people. However, all of the relevant evidence relates to administration in tablet form and using a standard dosage, despite alternative oral preparations (including solutions and extended-release tablets) being available and having potential advantages to the standard preparation. Gastrointestinal disorders (for example, nausea, vomiting, diarrhoea, abdominal pain and loss of appetite) are very common with metformin, especially at the start of treatment, and may be reduced or avoided with alternative preparations. Extended-release tablets and oral solutions may also be easier to swallow, as standard formulation metformin consists of large tablets. Further research would preferably consist of randomised controlled trials. Outcomes should include blood glucose control (preferably using measurement of HbA1c levels) and the child or young person's satisfaction with and adherence to treatment.

Source guidance details

Comes from guidance
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Date issued
August 2015

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No